It has been demonstrated that thalidomide's anti-angiogenic properties result in clear anti-tumor activity in a number of human malignancies. We studied thalidomide in a human melanoma severe combined immunodeficiency mouse xenotransplantation model. Thalidomide as a single agent showed a significant tumor reduction of 46% compared with the control group. Thalidomide combined with dacarbazine treatment markedly enhanced the anti-tumor effect of chemotherapy and showed a significant tumor reduction relative to the dacarbazine-only group (61%) and even more tumor reduction (74%) compared with the control group. We also measured clearly reduced levels of tumor necrosis factor-a in the thalidomide-treated group. A significantly lower microvessel density was encountered in the thalidomide treatment groups (thalidomide alone or combined with DTIC), underscoring the anti-angiogenic effect of thalidomide as a single agent as well as in combination with chemotherapy in this model. In line with these results, we observed a nearly 3-fold increase of apoptosis for the combination of thalidomide and DTIC compared with the rate of apoptotic cells in DTIC-only-treated melanoma xenotransplants. These data underline the rationale for combining dacarbazine-a cytotoxic agent-and thalidomide-an anti-angiogenic cytostatic agent-as a promising strategy for the treatment of melanoma.
Growth of tumors beyond a few millimeters requires the induction of new capillary blood vessel. The ability of solid tumors to induce new blood vessel formations, i.e. angiogenesis, is therefore crucial for tumor growth and development of metastasis. Ample evidence exists that inhibition of angiogenesis prevents tumor growth; therefore, anti-angiogenic therapy seems to be a rational and promising modality for therapy of human malignant disease (Carmeliet and Jain, 2000; Folkman, 2001) .
Thalidomide (a-N-phtalimidoglutarimide) is a derivative of glutamic acid. It has a broad spectrum of pharmacological immunological and other effects, including its well-known teratogenicity (Franks et al, 2004) . The mechanism of action of thalidomide is complex and not yet completely understood. It has been shown to suppress tumor necrosis factor-a (TNF-a) production by macrophages in vitro due to enhancement of the degradation of tumor-necrosis-factor-a mRNA (Porter and Jorge, 2002) .
Recent attention focused on the possibility of using thalidomide as an anti-angiogenic agent (Hales, 1999; Kumar et al, 2002) . D 'Amato et al (1994) first demonstrated that thalidomide exerted anti-angiogenic property in a rabbit corneal neovascularization assay (D' Amato et al, 1994) . Subsequently, animal studies demonstrated also that thalidomide inhibits tumor-induced angiogenesis in several cancers (lung cancer, colon cancer, sqamous cell carcinoma, esophageal cancer, myeloma) and produces a significant anti-tumor effect (Kotoh et al, 1999; Myoung et al, 2001; Ruddy and Majumdar, 2002; Yaccoby et al, 2002; Fujii et al, 2003; Li et al, 2003a, b) . In clinical trials, the most pronounced anti-tumor results were observed in patients with refractory multiple myeloma (Singhal et al, 1999) . But thalidomide was also studied in further advanced solid tumors in phase II such as recurrent gliomas, renal cancer, and hepatocellular carcinoma, showing promising significant anti-tumor effects (Fine et al, 2000; Singhal and Mehta, 2002) .
Melanoma is a prime example of a tumor with a poor response to adjuvant therapeutic strategies modalities like chemotherapy or radiation (Bajetta et al, 2002) . Melanomas are highly vascularized and it has been reported that increased vascularity correlates with poor prognosis (Ribatti et al, 2003; Valencak et al, 2004) . Thalidomide as a single agent did not show any objective responses in melanoma patients, but 35% of the patients experienced stable disease for a duration of 12-32 wk (Eisen et al, 2000; Pawlak and Legha, 2004) . A phase II trial combined treatment of thalidomide with temozolomide showed promising results.
In this study, 32% of the melanoma patients had an objective tumor response (Hwu et al, 2003) . This open-labeled phase II trial, however, was conceptualized as a single-arm study and did not compare the treatment groups within the same patient population. The mechanism of thalidomide's anti-tumor activity in melanoma remains unclear. Marriot et al (2003) showed in proliferation assays in vitro that a panel of tumor cells (colon, pancreatic, prostatic, and melanoma cells) treated with thalidomide did not exhibit reduced cell growth. It was also reported that thalidomide showed no growth inhibition on human colon cells in vitro, but a growth inhibition of over 40% in a mouse model in vivo (Kinuya et al, 2002) . Only recently, Ansiaux et al (2005) showed that thalidomide radiosensitizes fibrosarcoma tumors in mice, whereas the in vitro studies did not demonstrate any growth inhibition or sensitizing effect on fibrosarcoma cells.
We therefore focused our studies of thalidomide effects in melanoma on a well-established in vivo model system. In this study, we investigated the efficacy of thalidomide in a xenotransplantation model of human melanoma grown in severe combined immunodeficiency (SCID) mice. The aim of this study was to compare the effects of treatment on melanoma growth with thalidomide, control (carrier solution), dacarbazine (DTIC), and the combination of thalidomide and DTIC. We could demonstrate a clearly more pronounced effect on tumor growth by the combination of thalidomide and DTIC over single-agent treatment. This effect is associated with enhanced induction of apoptosis. Also, thalidomide treatment led to a significant decrease in microvessel densitity associated with a decrease of TNF-a levels.
Results
Tumor growth is reduced by the combination of thalidomide and DTIC Subcutaneous injection of human melanoma cells into SCID mice resulted in tumor-take in all animals inoculated. Figure 1 shows the tumor volumes of mice treated either with thalidomide, carrier solution (control), DTIC, or the combination of DTIC and thalidomide over 22 d (see also Table I ). The growth curve shows a clear difference in the reduction of tumor volume between the thalidomide and the control group. The mean tumor volume of the thalidomide group reached 155.9 AE 59.4 mm 3 (mean AE SD), which was 46% smaller than the mean tumor volume of the control group on day 22 (p ¼ 0.014).
On day 22, the tumor volume of the DTIC (only)-treated group showed a clear tumor reduction (34%) compared with the control (carrier solution) group (187.8 AE 32.0 mm 3 ). The difference of the mean volume of this group compared with the control group was also significant (p ¼ 0.003). Notably, the single-agent thalidomide and DTIC groups showed no significant differences in tumor volume (p ¼ NS).
The combination of thalidomide and DTIC (73.2 AE 23.8 mm 3 ) led to a significant reduction in tumor size on day 22 when compared with all other groups (po0.05). The combination of thalidomide and DTIC showed a 74% tumor size reduction compared with the control group (p ¼ 0.018).
All the animals tolerated the treatments well. There was no difference in body weight (data not shown) among the animals in the various treatment or control groups.
Inhibition of TNF-a plasma level by thalidomide It had been shown in vitro that thalidomide inhibits TNF-a in sti-
Figure 1
Inhibition of human melanoma growth in svere combined immunodeficiency (SCID) mice by the combination of thalidomide and dacarbazine (DTIC). SCID mice were injected subcutaneously with 2.5 Â 10 7 human melanoma cells (518 A2) into the lower left flank (n ¼ 10 animals per group). Starting one day after cell inoculation, thalidomide (administered daily at a dose of 400 mg per kg per day) or carrier solution (control) was administered for 22 d via the intraperitoneal route. From day 12 to 16, two of four groups also received daily dacarbazine (80 mg per kg per day i.p.). On day 22, the experiment was terminated. mulated human peripheral monocytes (Sampaio et al, 1992) . This inhibitory action was thought to be due to the enhancement of TNF-a mRNA degradation. Thalidomide has also been shown to act in the clinic as an anti-TNF-a agent during TNF-a-mediated diseases (Moreira et al, 1993) . We therefore focused on assessing TNF-a and measured TNF-a plasma levels after 22 d of treatment in all treatment groups. In accordance with the literature, we found a clear inhibition (59%) of total TNF-a levels in the peripheral blood of thalidomide-treated animals compared to vehicle-treated animals (Fig 2) . This difference was not significant (p ¼ 0.074). TNF-a is known to be elevated by DTIC in melanoma (Wack et al, 2002) . Not surprisingly, we did observe a clear elevation of TNF-a level in the DTIC singleagent group (17%) compared to the carrier solution (control) group. The differences of TNF-a plasma levels between the DTIC and thalidomide group were over 66% (p ¼ 0.06). The combination group showed higher TNF-a plasma levels than the thalidomide group; however, the values measured were still clearly lower than the ones in the control group.
Inhibition of microvessel density by thalidomide in human melanoma in SCID mice To gain further insight into the mechanism of action of thalidomide, we examined sections of the generated tumors for microvessel density (Fig 3a) . CD31 staining was used as a well-established marker for microvessels (Myoung et al, 2001; Valencak et al, 2004) . The mean number of microvessels of tumors treated with thalidomide (alone or in combination with DTIC) was significantly reduced compared with the control (carrier solution) group and the DTIC group (pp0.05) (Fig 3b) . This significant reduction of microvessel density by thalidomide indicates the anti-angiogenic potential of thalidomide in this model system.
Induction of apoptosis by the combination of thalidomide and DTIC It is well accepted that DTIC exerts its antitumor activity by induction of apoptosis (Wack et al, 2002) .
For thalidomide, the evidence is less clear and somewhat conflicting. Very recently, it was shown that thalidomide evokes apoptosis in human blood monocytes in a time-and concentration-dependent matter (Gockel et al, 2004) . In line with these observations, we determined the number of apoptotic cells in xenograft tumors treated with thalidomide, DTIC, or the combinations of both agents. Thalidomide alone as well as carrier solution (control) treatment showed no clear change in the rate of apoptotic cells compared with the control group (see Fig 4) . Single-agent DTIC resulted in a moderate increase of apoptosis by 1.8% AE 0.4% SD compared to the control group. The combination group of thalidomide and DTIC, however, showed a clear increase of 5.2% AE 1.2% SD of apoptotic cells compared with the control group. Detailed results are summarized in Table I .
Discussion
This study investigates the mechanism of action and the anti-tumor potential of thalidomide as a single agent and in combination with DTIC in a xenotransplantation model of human melanoma. Even when administered as a single agent, thalidomide showed a clear tendency to inhibit tumor growth. In consideration of thalidomide's potential as an adjuvant to chemotherapy, our data document a clear advantage of the thalidomide combination therapy over DTIC single-agent treatment.
A Phase II study of temozolomide plus thalidomide showed significant clinical activity (Hwu et al, 2003) . On the other hand, temozolomide, a active metabolite of DTIC, did not show significant differences in the overall response rate compared with DTIC (Middleton et al, 2000) . The results of Hwu et al (2003) are in line with our findings. Thalidomide has been reported to use its anti-tumor properties via inhibition of angiogenesis in a variety of models of myeloma, esophageal, lung, colon cancer, and oral squamous cell carcinoma (Kotoh et al, 1999; Myoung et al, 2001; Yaccoby et al, 2002; Fujii et al, 2003; Li et al, 2003b) . The mechanism of action in melanoma, however, is only poorly understood. This study appears to clearly demonstrating the inhibition of angiogensis by thalidomide in human melanoma. It was the aim of the study to explore the anti-angiogenic potential of thalidomide against non-established melanomas resembling the clinical situation of an adjuvant treatment against micro-metastases after excision of a high-risk primary melanoma. Therefore, we started the treatment with thalidomide one day after melanoma cell inoculation. It is of interest to note that thalidomide mono-therapy using a comparable administration schedule led to clearly reduced numbers in lung and liver metastases in a murine xenotransplantation model of hepatocellular carcinoma (Zhang et al, 2005) . Several reports link the inhibition of growth factors like VEGF and bFGF to the anti-angiogenic effect of thalidomide (Myoung et al, 2001; Li et al, 2003a) . In our study, however, immunohistochemical staining of VEGF and bFGF did not show any regulation of these factors by thalidomide (data not shown). In line with our results, no detectable VEGF or bFGF regulation has been reported in other animal studies despite a clear anti-tumor effect (Yaccoby et al, 2002; Fujii et al, 2003) . It is also reported that thalidomide blocks the action of VEGF or bFGF on endothelial cells during angiogenesis rather than blocking VEGF production/regulation (Amato, 2002; Gelati et al, 2003) .
Thalidomide has also been described as an inhibitor of TNF-a, probably by enhancing the degradation of TNF-a mRNA ( Moreira et al, 1993; Ching et al, 1995; Argiles et al, 1998) . Serum of mice mice treated with single-agent thalidomide showed a clear reduction of TNF-a compared with serum of mice in the control group. This finding was somewhat surprising since most anti-tumor strategies using the death receptor-ligand TNF tend to facilitate a local increase of TNF around the tumor. An increased level of mRNA of TNF-a in melanoma was found after treatment with DTIC (Wack et al, 2002) . Stebbing et al (2001) showed a statistically significant decrease of TNF-a level in serum in patients with renal cancer who received high doses of thalidomide and responded with stable disease or objective response. In our study, we observed a direct correlation between the decrease of TNF-a level in mice serum and the anti-tumor effect of thalidomide in melanoma. The detailed mechanism and the significance of this regulation, however, remain to be elucidated. Recently, it was shown that thalidomide induces apoptosis in monocytes by using a cytochrome cdependent pathway (Gockel et al, 2004) . Also, thalidomide treatment resulted in an increase of apoptosis in human T leukemic cells as evidenced by an increase of caspases-3 activity (Ezell et al, 2003) . Furthermore, a novel subclass of thalidomide analogue (SelCID-3) induced apoptosis in various tumor cell lines through the induction of G 2 -M cell cycle arrest, which in turn led to caspase 3-mediated apoptosis (Marriott et al, 2003) . Surprisingly, in our study, we could not detect a clear increase of apoptotic cells in the tumors that were treated with thalidomide alone. The combination of thalidomide and DTIC, however, resulted in a nearly 3-fold increase of apoptotic cells (5.2%) compared with tumors treated with DTIC alone (1.8%). These data indicate that thalidomide clearly facilitates the induction of apoptosis induced by DTIC in a supra-additive manner. Similarly, the combination of paclitaxel and thalidomide showed significant tumor growth retardation in a human colon cancer xenograft model. Furthermore, this study noticed a trend of increased apoptotic index in the combination group (Fujii et al, 2003) .
The concept of either lowering the dose of a given chemotherapeutic agent or supplementing a particularly side-effect-prone agent in a combinatorial regime with antiangiogenic agents is aimed at improving the effect and tolerability of cancer therapy (Verheul et al, 1999) . The blocking of vasculature of tumors can be expected to cause the death of cells farthest from capillaries, ultimately leading to a decreased tumor mass and an increased efficiency of administered chemotherapy drugs. The angiogenesis inhibitors could also prevent further growth and progression to metastatic disease after a chemotherapeutic regimen (Teicher et al, 1992; Amato, 2002) .
The ability to achieve better anti-tumor responses by combining dacarbazine-a cytotoxic agent-and thalidomide-an anti-angiogenic cytostatic agent-may qualify as a rational treatment approach to improve the outcome of melanoma.
Materials and Methods
Thalidomide Thalidomide powder was kindly provided by Grunenthal (Aachen, Germany). It was suspended in 1% carboxyme-thylcellulose (CMC), 0.1% Tween 80, and phosphate-buffered saline (PBS, Gibco BRL, Paisley, Scotland) by extensive stirring.
Cell culture The human melanoma cell line 518 A2 (Jansen et al, 1998) was maintained in basal tissue culture medium (DMEM, Gibco BRL) supplemented with 8% fetal calf serum (FCS) and antibiotics, in a humidified 5% CO 2 , 95% ambient air atmosphere of 371C.
Experimental animals and tumor treatment in SCID mice Pathogen-free female C.B-17 scid/scid (SCID) mice, 4-6 wk old, were obtained from Bomholtgard Breeding and Research Center (Bomice, Denmark) and randomly assigned to the experimental groups. The animals were housed in laminar flow racks and microisolator cages under specific pathogen-free conditions and received autoclaved food and water, but no antibiotic prophylaxis. SCID mice (n ¼ 40) were injected subcutaneously with 2.5 Â 10 7 human melanoma cells (518 A2) into the lower left flank. Four groups (n ¼ 10 animals per group) were stratified to receive either (1) thalidomide þ carrier solution;
(2) carrier solution; (3) dacarbazine þ carrier solution; and (4) dacarbazine þ thalidomide þ carrier solution. One day after cell inoculation, groups 1 and 4 received thalidomide via the intraperitoneal route at a dose of 400 mg per kg per day (Ruddy and Majumdar, 2002) for 22 d. Groups 2 and 3 also received daily injections for 22 days, but of the carrier solution (control). From day 12 to 16, groups 3 and 4 additionally received dacarbazine (80 mg per kg per day) intraperitoneally on a daily basis. The length and width of the subcutaneous tumors were measured using a caliper twice a week (volume (mm 3 ) ¼ length Â width 2 ). On day 22, blood was collected and the experiment was terminated. This study was approved by the Medical University of Vienna's animal welfare committee.
Quantitative estimate of human TNF-a by ELISA Levels of TNFa in serum were determined using an ELISA (Quantikine Mouse TNF-a kit; R&D Systems, Minneapolis, Minnesota) according to the manufacturer's instructions. Briefly, serum samples were added to microwells coated with monoclonal antibodies against the cytokine measured. After incubation, wells were washed and then an enzyme-linked polyclonal anti-TNF-a antibody was added. Following a new incubation and a subsequent wash that removed any unbound antibody-enzyme reagent, substrate was added. After incubation, an amplifier solution was added, leading to color development. Absorbance was measured at 450 nm, and the results were calculated from a standard curve produced by serial dilutions of a given cytokine sample.
Histopathological examination For histopathology studies, macroscopically normal tissues (brain, lung, heart, liver spleen, kidney, and small intestine) and tumor tissue were obtained from all animals, and then fixed in 7.5% neutral-buffered formalin, dehydrated, and embedded in paraffin using routine methods. Glass slides with 5 mm tissue sections were prepared and stained with hematoxylin and eosin. Additional tumor tissue was frozen and used for immunohistological stainings that were performed with the use of the avidin-biotin-peroxidase complex method. Hamster antimouse polyclonal antibody (Endogen, Boston, Massachusetts) was used for CD31 (PECAM). 5 mm frozen tumor sections were incubated with the primary antibody (dilution 1:75) at room temperature for 1 h. The subsequent steps were carried out using LSAB Kit (DAKO, Glostrup, Denmark) with a second biotin-conjugated anti-hamster antibody (DAKO).
Microvessel count The CD31-stained sections were scanned at a low magnification to identify the highest vascular area, and three fields were chosen for further assessment. The numbers of stained discrete microvessels/field were counted at Â 200 magnification (0.74 mm 2 per area). Vessel counting was performed in a blinded manner. Average vessel numbers in three fields as well as the mean vessel number and SD of each group were calculated.
Evaluation of apoptosis TdT-mediated dUTP nick end-labeling (TUNEL) immunohistochemistry was performed in tumor xenotransplants according to the manufacturer's protocol (Roche Diagnostics, Mannheim, Germany). Only comparable sections of the outer layers of the tumors without signs of necrotic areas were analyzed. The apoptotic index was determined by fluorescence microscopy blinded to the treatment groups.
Statistical analysis Statistical significance of differences between treatment groups was calculated by using one-way ANOVA and post-test comparing means using the Bonferroni's test for post hoc testing (SPSS, Chicago Illinois). p-Values of p0.05 were considered to be of statistical significance.
